Prefer a chat interface with context about you and your work?
Progression-free survival: Does a correlation with survival justify its role as a surrogate clinical endpoint?
We thank Becker et al1 for their thoughtful editorial on our article2 describing progression-free survival (PFS) as a surrogate endpoint for overall survival (OS) in renal cancer clinical trials. We agree that our data do not necessarily support the use of PFS as a surrogate endpoint for OS across the …